Imaging beyond the diagnosis: Image-guided enzyme/prodrug cancer therapy

Xinyi Tong, Xishan Chen, Cong Li

Research output: Contribution to journalArticle

Abstract

The ideal therapy would target cancer cells while sparing normal tissue. However, in most conventional chemotherapies normal cells are damaged together with cancer cells resulting in the unfortunate side effects. The principle underlying enzyme/prodrug therapy is that a prodrug-activating enzyme is delivered or expressed in tumor tissue following which a non-toxic prodrug is administered systemically. Non-invasive imaging modalities can fill an important niche in guiding prodrug administration when the enzyme concentration is detected to be high in the tumor tissue but low in the normal tissue. Therefore, high therapeutic efficacy with minimized toxic effect can be anticipated. This review introduces the latest developments of molecular imaging in enzyme/prodrug cancer therapies. We focus on the application of imaging modalities including magnetic resonance imaging, position emission tomography and optical imaging in monitoring the enzyme delivery/expression, guiding the prodrug administration and evaluating the real-time therapeutic response in vivo.

Original languageEnglish (US)
Pages (from-to)4-12
Number of pages9
JournalActa Biochimica et Biophysica Sinica
Volume43
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Fingerprint

Prodrugs
Imaging techniques
Enzymes
Tissue
Neoplasms
Tumors
Therapeutics
Cells
Enzyme Therapy
Molecular imaging
Molecular Imaging
Chemotherapy
Poisons
Optical Imaging
Magnetic resonance
Tomography
Magnetic Resonance Imaging
Drug Therapy
Monitoring

Keywords

  • cancer
  • enzyme
  • molecular imaging
  • prodrug
  • therapy

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics

Cite this

Imaging beyond the diagnosis : Image-guided enzyme/prodrug cancer therapy. / Tong, Xinyi; Chen, Xishan; Li, Cong.

In: Acta Biochimica et Biophysica Sinica, Vol. 43, No. 1, 01.2011, p. 4-12.

Research output: Contribution to journalArticle

Tong, Xinyi ; Chen, Xishan ; Li, Cong. / Imaging beyond the diagnosis : Image-guided enzyme/prodrug cancer therapy. In: Acta Biochimica et Biophysica Sinica. 2011 ; Vol. 43, No. 1. pp. 4-12.
@article{afa41d32e9044a4aa80e3d188a2d95f5,
title = "Imaging beyond the diagnosis: Image-guided enzyme/prodrug cancer therapy",
abstract = "The ideal therapy would target cancer cells while sparing normal tissue. However, in most conventional chemotherapies normal cells are damaged together with cancer cells resulting in the unfortunate side effects. The principle underlying enzyme/prodrug therapy is that a prodrug-activating enzyme is delivered or expressed in tumor tissue following which a non-toxic prodrug is administered systemically. Non-invasive imaging modalities can fill an important niche in guiding prodrug administration when the enzyme concentration is detected to be high in the tumor tissue but low in the normal tissue. Therefore, high therapeutic efficacy with minimized toxic effect can be anticipated. This review introduces the latest developments of molecular imaging in enzyme/prodrug cancer therapies. We focus on the application of imaging modalities including magnetic resonance imaging, position emission tomography and optical imaging in monitoring the enzyme delivery/expression, guiding the prodrug administration and evaluating the real-time therapeutic response in vivo.",
keywords = "cancer, enzyme, molecular imaging, prodrug, therapy",
author = "Xinyi Tong and Xishan Chen and Cong Li",
year = "2011",
month = "1",
doi = "10.1093/abbs/gmq113",
language = "English (US)",
volume = "43",
pages = "4--12",
journal = "Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica",
issn = "1672-9145",
publisher = "Shanghai Kexue Jishu Chubanshe/Shanghai Scientific & Technical Publishers",
number = "1",

}

TY - JOUR

T1 - Imaging beyond the diagnosis

T2 - Image-guided enzyme/prodrug cancer therapy

AU - Tong, Xinyi

AU - Chen, Xishan

AU - Li, Cong

PY - 2011/1

Y1 - 2011/1

N2 - The ideal therapy would target cancer cells while sparing normal tissue. However, in most conventional chemotherapies normal cells are damaged together with cancer cells resulting in the unfortunate side effects. The principle underlying enzyme/prodrug therapy is that a prodrug-activating enzyme is delivered or expressed in tumor tissue following which a non-toxic prodrug is administered systemically. Non-invasive imaging modalities can fill an important niche in guiding prodrug administration when the enzyme concentration is detected to be high in the tumor tissue but low in the normal tissue. Therefore, high therapeutic efficacy with minimized toxic effect can be anticipated. This review introduces the latest developments of molecular imaging in enzyme/prodrug cancer therapies. We focus on the application of imaging modalities including magnetic resonance imaging, position emission tomography and optical imaging in monitoring the enzyme delivery/expression, guiding the prodrug administration and evaluating the real-time therapeutic response in vivo.

AB - The ideal therapy would target cancer cells while sparing normal tissue. However, in most conventional chemotherapies normal cells are damaged together with cancer cells resulting in the unfortunate side effects. The principle underlying enzyme/prodrug therapy is that a prodrug-activating enzyme is delivered or expressed in tumor tissue following which a non-toxic prodrug is administered systemically. Non-invasive imaging modalities can fill an important niche in guiding prodrug administration when the enzyme concentration is detected to be high in the tumor tissue but low in the normal tissue. Therefore, high therapeutic efficacy with minimized toxic effect can be anticipated. This review introduces the latest developments of molecular imaging in enzyme/prodrug cancer therapies. We focus on the application of imaging modalities including magnetic resonance imaging, position emission tomography and optical imaging in monitoring the enzyme delivery/expression, guiding the prodrug administration and evaluating the real-time therapeutic response in vivo.

KW - cancer

KW - enzyme

KW - molecular imaging

KW - prodrug

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=78650740921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650740921&partnerID=8YFLogxK

U2 - 10.1093/abbs/gmq113

DO - 10.1093/abbs/gmq113

M3 - Article

C2 - 21134886

AN - SCOPUS:78650740921

VL - 43

SP - 4

EP - 12

JO - Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica

JF - Sheng wu hua xue yu sheng wu wu li xue bao Acta biochimica et biophysica Sinica

SN - 1672-9145

IS - 1

ER -